BIOTON S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.505 PLN | 0.00% |
|
-0.43% | -1.82% |
| Mar. 28 | BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
ETFs positioned on BIOTON S.A.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.54% | - |
Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -1.82% | 74.34M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- BIO Stock
- Funds and ETFs BIOTON S.A.
